Humana holds the cleaner structural position, with growth as the main driver and profitability adding further support. Carl Zeiss Meditec still has the edge on valuation, which keeps the comparison from looking entirely one-sided. On the market side, Humana is in better shape — its trend is intact while Carl Zeiss Meditec's trend has broken down. That puts structure and market broadly in agreement — Humana's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (AFX.DE: HDAX, HUM: S&P 500).
The clearest separation starts in growth, but profitability adds another real layer to the result. The overall score gap is 10 points in favour of Humana Inc..
This pair is matched through long-term financial trajectory similarity within the selected peer universe.
The pair shares a valid long-term profile match, but the trajectories are not especially close.
The match is driven mainly by revenue stability and investment intensity.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Humana Inc. is cheaper, but Carl Zeiss Meditec AG is still stronger.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where AFX.DE and HUM each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Revenue growth reinforces the category-level growth lead.
Absolute pricing still looks more supportive for Carl Zeiss Meditec, with a forward P/E that is 3.7 turns lower there.
Growth is the clearest driver of the lead, with profitability adding further support — though valuation still provides a real counterweight.
Break down the AFX.DE vs HUM comparison across all dimensions with the full interactive tool.
Explore how AFX.DE and HUM each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.